Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12132643 | 0.81 | METAP2 (0.50) | METAP2NPY5RNISCHADORA2AADORA2B | |
| SCHEMBL12410792 | 0.76 | BTK (0.45) | METAP2NPY5RLMNACYP1A2ALDH1A1 | |
| SCHEMBL15996480 | 0.74 | NPY5R (0.43) | METAP2NPY5RNISCHADORA2AADORA2B | |
| SCHEMBL5636290 | 0.73 | METAP2 (0.44) | METAP2NPY5RNISCHADORA2AADORA2B | |
| SCHEMBL24317547 | 0.72 | — | — | |
| SCHEMBL12197780 | 0.69 | GSK3B (0.46) | NPY5RLMNACYP1A2ALDH1A1 | |
| SCHEMBL418267 | 0.67 | KIF11 (0.44) | METAP2NPY5RNISCHDHODHSMN1; SMN2 | |
| SCHEMBL15996725 | 0.67 | NPY5R (0.46) | METAP2NPY5RNISCHADORA2AADORA2B | |
| SCHEMBL20118772 | 0.66 | NPC1 (0.37) | NISCHPIM1P2RX7LMNACYP1A2 | |
| SCHEMBL78566 | 0.65 | NISCH (0.50) | METAP2NISCHPIM1P2RX7CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | METAP2 3668/4885NPY5R 149/4885NISCH 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.